Drug Search Results
More Filters [+]

Cerdulatinib

Alternative Names: cerdulatinib, prt062070, ALXN2075, ALXN-2075, DMVT-502, DMVT502
Latest Update: 2024-04-19
Latest Update Note: PubMed Publication

Product Description

An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cerdulatinib)

Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,SYK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cerdulatinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Follicular Lymphoma|T-Cell Peripheral Lymphoma

Phase 2: Vitiligo|T-Cell Leukemia|Follicular Lymphoma|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|T-Cell Peripheral Lymphoma|Lymphocytic Chronic B-Cell Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CELTIC-1

P3

Withdrawn

Follicular Lymphoma|T-Cell Peripheral Lymphoma

2022-12-31

52%

NCT01994382

P2

Completed

Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|T-Cell Peripheral Lymphoma|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Follicular Lymphoma|T-Cell Leukemia

2020-12-15

DMVT-502-2101

P2

Completed

Vitiligo

2020-11-03

48%

NCT04757259

N/A

No longer available

Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin

None

Recent News Events